The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients

Chris Weir; Annika Oksa; Jennifer Millar; Miles Alexander; Nicola Kynoch; Zoe Walton-Weitz; Peter Mackenzie-Wood; Felicia Tam; Hope Richards; Richard Naylor; Katrina Cheng; Peter Bennett; Nikolai Petrovsky; Rachel Allavena

doi:10.3390/vetsci5040087

The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients

Chris Weir, Annika Oksa, Jennifer Millar, Miles Alexander, Nicola Kynoch, Zoe Walton-Weitz, Peter Mackenzie-Wood, Felicia Tam, Hope Richards, Richard Naylor, Katrina Cheng, Peter Bennett, Nikolai Petrovsky, Rachel Allavena

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

45 Downloads (Pure)

Abstract

Canine cancer rates are similar to humans, though the therapeutic options might be limited. Inducing a patient's own immune system to have an anti-tumor response is an attractive approach to cancer therapy. In this safety study, autologous tumor vaccines produced specifically for each canine patient were combined with Advax™, a novel non-inflammatory immunomodulator and vaccine adjuvant and were tested for safety in a diverse range of patient presentations alone or in combination with other treatments. Canine patients had their tumor biopsied, debulked or resected and the tumor antigens were processed into an autologous vaccine formulated with Advax™ adjuvant with or without rhizavidin as an additional immune stimulant. Patients treated early in the trial received two intramuscular (IM) doses, 2 weeks apart. As the study progressed and no issues of safety were observed, the protocol was changed to weekly vaccinations for 4 weeks followed by monthly booster shots. Over the 150 I.M injections delivered to date, the vaccine was found to be very safe and no significant adverse reactions were observed. These results justify ongoing development and future controlled studies of this autologous vaccine approach.

Original language	English
Article number	87
Number of pages	15
Journal	Veterinary Sciences
Volume	5
Issue number	4
DOIs	https://doi.org/10.3390/vetsci5040087
Publication status	Published - 12 Oct 2018

Bibliographical note

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Keywords

Adjuvant
Advax™
Autologous
Canine
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/vetsci5040087Licence: CC BY

Weir_Safety_P2018Final published version, 1.19 MBLicence: CC BY

Cite this

@article{3465c69af0cb490392666267b15ed625,

title = "The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients",

abstract = "Canine cancer rates are similar to humans, though the therapeutic options might be limited. Inducing a patient's own immune system to have an anti-tumor response is an attractive approach to cancer therapy. In this safety study, autologous tumor vaccines produced specifically for each canine patient were combined with Advax{\texttrademark}, a novel non-inflammatory immunomodulator and vaccine adjuvant and were tested for safety in a diverse range of patient presentations alone or in combination with other treatments. Canine patients had their tumor biopsied, debulked or resected and the tumor antigens were processed into an autologous vaccine formulated with Advax{\texttrademark} adjuvant with or without rhizavidin as an additional immune stimulant. Patients treated early in the trial received two intramuscular (IM) doses, 2 weeks apart. As the study progressed and no issues of safety were observed, the protocol was changed to weekly vaccinations for 4 weeks followed by monthly booster shots. Over the 150 I.M injections delivered to date, the vaccine was found to be very safe and no significant adverse reactions were observed. These results justify ongoing development and future controlled studies of this autologous vaccine approach.",

keywords = "Adjuvant, Advax{\texttrademark}, Autologous, Canine, Vaccine",

author = "Chris Weir and Annika Oksa and Jennifer Millar and Miles Alexander and Nicola Kynoch and Zoe Walton-Weitz and Peter Mackenzie-Wood and Felicia Tam and Hope Richards and Richard Naylor and Katrina Cheng and Peter Bennett and Nikolai Petrovsky and Rachel Allavena",

note = "This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0). ",

year = "2018",

month = oct,

day = "12",

doi = "10.3390/vetsci5040087",

language = "English",

volume = "5",

journal = "Veterinary Sciences",

issn = "2306-7381",

publisher = "MDPI",

number = "4",

}

TY - JOUR

T1 - The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients

AU - Weir, Chris

AU - Oksa, Annika

AU - Millar, Jennifer

AU - Alexander, Miles

AU - Kynoch, Nicola

AU - Walton-Weitz, Zoe

AU - Mackenzie-Wood, Peter

AU - Tam, Felicia

AU - Richards, Hope

AU - Naylor, Richard

AU - Cheng, Katrina

AU - Bennett, Peter

AU - Petrovsky, Nikolai

AU - Allavena, Rachel

N1 - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

PY - 2018/10/12

Y1 - 2018/10/12

N2 - Canine cancer rates are similar to humans, though the therapeutic options might be limited. Inducing a patient's own immune system to have an anti-tumor response is an attractive approach to cancer therapy. In this safety study, autologous tumor vaccines produced specifically for each canine patient were combined with Advax™, a novel non-inflammatory immunomodulator and vaccine adjuvant and were tested for safety in a diverse range of patient presentations alone or in combination with other treatments. Canine patients had their tumor biopsied, debulked or resected and the tumor antigens were processed into an autologous vaccine formulated with Advax™ adjuvant with or without rhizavidin as an additional immune stimulant. Patients treated early in the trial received two intramuscular (IM) doses, 2 weeks apart. As the study progressed and no issues of safety were observed, the protocol was changed to weekly vaccinations for 4 weeks followed by monthly booster shots. Over the 150 I.M injections delivered to date, the vaccine was found to be very safe and no significant adverse reactions were observed. These results justify ongoing development and future controlled studies of this autologous vaccine approach.

AB - Canine cancer rates are similar to humans, though the therapeutic options might be limited. Inducing a patient's own immune system to have an anti-tumor response is an attractive approach to cancer therapy. In this safety study, autologous tumor vaccines produced specifically for each canine patient were combined with Advax™, a novel non-inflammatory immunomodulator and vaccine adjuvant and were tested for safety in a diverse range of patient presentations alone or in combination with other treatments. Canine patients had their tumor biopsied, debulked or resected and the tumor antigens were processed into an autologous vaccine formulated with Advax™ adjuvant with or without rhizavidin as an additional immune stimulant. Patients treated early in the trial received two intramuscular (IM) doses, 2 weeks apart. As the study progressed and no issues of safety were observed, the protocol was changed to weekly vaccinations for 4 weeks followed by monthly booster shots. Over the 150 I.M injections delivered to date, the vaccine was found to be very safe and no significant adverse reactions were observed. These results justify ongoing development and future controlled studies of this autologous vaccine approach.

KW - Adjuvant

KW - Advax™

KW - Autologous

KW - Canine

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85058624342&partnerID=8YFLogxK

U2 - 10.3390/vetsci5040087

DO - 10.3390/vetsci5040087

M3 - Article

AN - SCOPUS:85058624342

SN - 2306-7381

VL - 5

JO - Veterinary Sciences

JF - Veterinary Sciences

IS - 4

M1 - 87

ER -

The safety of an adjuvanted autologous cancer vaccine platform in canine cancer patients

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this